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GRAPHICAL ABSTRACTBackground: There havebeen few studies conducted on the efficacy
and safety of specific immunotherapywith allergen extracts of fungi
compared with other allergen extracts, and there are no data on the
major allergen Alt a 1 of the fungus Alternaria alternata.
Objectives: We sought to evaluate the efficacy and safety of
subcutaneous immunotherapy with 2 different doses of Alt a 1
in patients with rhinoconjunctivitis caused by sensitization to A
alternata.
Method: We performed a multicenter, randomized, double-
blind, placebo-controlled trial with Alt a 1 administered
subcutaneously in patients with allergic rhinoconjunctivitis with
or without controlled asthma aged 12 to 65 years. Three groups
were included: the placebo group and active groups receiving
0.2 or 0.37 mg of Alt a 1 per dose. The main end point was the
combined symptom and medication score. Secondary end points
were cutaneous reactivity and serum IgE and IgG4 levels to AltFrom aComplejo Hospitalario de Navarra, Pamplona; bHospital Universitario Dr. Peset,
Valencia; cHospital de Manises, Valencia; dHospital Universitario La Fe, Valencia;
eHospital Universitario Prıncipe de Asturias, Alcala de Henares, Madrid; fHospital
Universitario Nuestra Se~nora del Perpetuo Socorro, Albacete; gHospital del Sureste,
Arganda del Rey, Madrid; hHospital Universitario de Ciudad Real; iHospital General,
Universitario de Alicante; jHospital Regional Universitario Carlos Haya, Malaga; and
kDiater Laboratorios S.A., Leganes, Madrid.
Supported by Laboratorios Diater S.A., Leganes, Madrid, Spain.
Disclosure of potential conflict of interest: A. I. Tabar reports and declares that she is the
coordinating investigator of the clinical trial. D. Rodrıguez and R. Palacios report and
declare that they are employees of the company sponsoring the clinical trial, Diater
Laboratorios. The rest of the authors declare that they have no relevant conflicts of
interest.
216a 1. Recorded adverse reactions were graded according to
World Allergy Organization criteria.
Results: There were significant reductions in the combined
symptom and medication score for the 0.37-mg dose of Alt a 1
compared with placebo at 12 months of treatment. Reduced
cutaneous reactivity and IgE levels, together with increased
IgG4 levels, were demonstrated for the 2 active groups versus
the placebo group. A similar safety profile was found for both
active groups compared with the placebo group. No serious
adverse drug reactions were reported.
Conclusion: Immunotherapy with Alt a 1 was efficacious and
safe, reducing the symptoms and medication consumption
associated with rhinoconjunctivitis after only 1 year of
treatment. The clinical benefits were associated with reduced
skin reactivity and specific IgE levels and increased IgG4 levels.
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ADR: Adverse drug reaction
AE: Adverse event
CRF: Case report form
CSMS: Combined symptom and medication score
ITT: Intention to treat
PP: Per-protocol
WAO: World Allergy Organization
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Alternaria species represent probably the most important
saprophytic genus from the fungal allergy point of view.1
Alternaria alternata is the most abundant and best studied
species, given its importance as an aeroallergen with a worldwide
distribution and a high rate of involvement in patients with
allergic diseases, such as rhinitis and asthma.2 A alternata
predominates in outdoor environments, and its spores are
principally involved in sensitization,3 although its categorization
and importance as an indoor allergen have also been established.4
Alt a 1 is the predominant allergen of the 17 reactive IgE proteins
identified in A alternata,5 12 of which are described in
the International Union of Immunological Societies
(www.allergen.org). It is mainly present in the spore wall6 and
responds molecularly to a 30-kDa dimer specific to the Fungi
kingdom,with ab-barrel structure and an unknown biological func-
tion.7 In reducing conditions it can be separated into subunits of 16.4
and 15.3 kDa, respectively. Sensitization to Alt a 1 is identified in
more than 90% of patients with allergy to A alternata.2,5
The availability of Alt a 1 isolated in its natural form for use in
in vivo diagnoses and immunotherapy provides an alternative to
the variability of whole allergenic extracts from molds.8,9 Alt a
1 is not present only in A alternata but is an orthologous allergen
present in other species of the order Pleosporales, such as
Stemphylium botryosum and Ulocladium botrytis. This would
make it possible to apply the diagnosis and treatment with Alt a
1 to patients sensitized to these fungi as well.10-12
After a first clinical trial, classified as phase IV by the Agencia
Espa~nola de Medicamentos y Productos Sanitarios, which
demonstrated the safety of treatment with Alt a 1 in patients
with symptoms of rhinitis and asthma caused by sensitization to A
alternata,13 the aim of this trial was to evaluate the efficacy and
safety of a higher dose of Alt a 1 and compare it with the
previously tested dose.METHODS
Trial design
Amulticenter, randomized, double-blind, parallel-group, placebo-controlled
clinical trial of differing concentrations of Alt a 1 was designed. Randomization
was carried out by the sponsor in blocks of 6 for each participating hospital. The
treatments were assigned on a 1:1:1 basis so that each block of 6 contained 2
high-dose treatments, 2 low-dose treatments, and 2 placebos. The trial was
authorized by the Clinical Research Ethics Committee, Hospital Complex of
Navarra, Spain, and the Spanish Agency of Medicines and Medical Devices
(EudraCT 2010-024440-15) and included 113 patients from 17 Spanish
hospitals. The trial began in 2012 and finished in 2016. The treatment schedule
is described in Fig 1 (see Table E1 in this article’s Online Repository at
www.jacionline.org). At 12 months, the placebo group was incorporated into
the group receiving the highest dose (placebo-high dose). A 30-day follow-up
period with 1 visit was included at the end of the study (Fig 1).
The trial was designed in accordance with European Medicines Agency
guidelines on the production and control of allergens,14 clinical development
in immunotherapy with allergens,15 and good clinical practice.16
Patients
Patients more than 12 years old with a clinical history consistent with
allergic rhinitis/rhinoconjunctivitis associated with fungal exposure and withor without mild or moderate asthma were recruited.17 The patients’
sensitization was demonstrated, and skin test follow-up was performed
throughout the trial by using skin prick tests (wheal diameter >_3 mm) with
whole extract of A alternata (2HEPD) and the major allergen, purified natural
Alt a 1, at a concentration of 10 mg/mL (Diater, Madrid, Spain). Levels of
specific IgE to Alt a 1 were determined by using a commercially available
system (Thermo Fisher Scientific, Waltham, Mass), with a cutoff value of
0.7 kU/L or greater. Patients polysensitized to epithelia and mites were not
selected for this study nor were those with uncontrolled asthma and those
who had received fungal immunotherapy in the 3 years before initiation of
the trial.
We recruited 113 patients, 111 of whom received at least 1 administration
(intention to treat [ITT]), who were assigned as follows: 29 to placebo, 37 to
low-doseAlt a 1 (0.2mg ofAlt a 1/dose), and 45 to high-dose Alt a 1 (0.37mg of
Alt a 1/dose, Fig 2): 66weremale (59.5%) and 45were female (40.5%) subjects,
and 63 (56.8%) were aged 18 years or more and 48 (43.2%) were aged 17 years
or less. The mean age was 21 years (SD, 8 years; range, 12–44 years).Immunotherapy with Alt a 1
The major allergen Alt a 1 isoform 1.0101 (UniProt P79085) was purified
from an extract of A alternata by using ion exchange and size exclusion
chromatography, with a purity of greater than 95%.13
Alt a 1 was stabilized by means of lyophilization in single-dose vials with
mannitol as a cryoprotectant at concentrations of 0.025 mg per vial and
0.046 mg per vial for the induction dose and 0.25 mg per vial and 0.46 mg per
vial for the maintenance dose. Physiologic saline was used as the diluent, with
aluminum hydroxide (0.83mg per vial) as an adjuvant. The maximum volume
of subcutaneous administration was 0.8 mL.
Trial end points
Themain study end point was the combined symptom andmedication score
(CSMS). Nasal symptoms recorded were nasal congestion, pruritus, mucus
production, and sneezing. A score based on symptom severity was used: 0,
no symptoms; 1, mild symptoms; 2, moderate symptoms; and 3, severe
symptoms. Ocular symptoms recorded were hyperemia, pruritus, tearing, and
exudate; an identical severity score was used. The score of each symptomwas
added up, resulting in a score ranging from 0 to 24. The result was then divided
by the number of symptoms evaluated, resulting in a final symptom score
ranging from 0 to 3. All patients had access to identical rescue medication
when necessary. Medication use was graded as follows: 0, no rescue
medication; 1, antihistamines (topical: levocabastine and/or systemic:
loratadine); 2, nasal corticosteroids (budesonide); and 3, oral corticosteroids
(deflazacort). Themain end point was calculated at each of the visits during the
2 years of the trial for each of the groups by calculating mean symptoms
recorded and mean medication consumed, both on a scale of 0 to 3, and
dividing the sum of these by 2. This variable was recorded by patients during
each month of the trial.
Secondary end points included serum Alt a 1–specific IgE and IgG4 levels
(ImmunoCAP; Thermo Fisher Scientific) determined at baseline and at 3, 12,
18, and 24 months. Changes in cutaneous reactivity during immunotherapy
with skin prick tests to A alternata and Alt a 1 (Diater) were observed at base-
line and 12 and 24 months.
FIG 1. Study design. Low dose, 0.2 mg of Alt a 1 per dose; high dose, 0.37 mg of Alt a 1 per dose.
FIG 2. Flow diagram of subject disposition.
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classified according to the MedDRA dictionary. Adverse drug reactions
(ADRs) were graded according to World Allergy Organization (WAO)
criteria.18Statistical analysis
It was hypothesized that patients assigned to the active medication groups
should show a reduction of 30% or greater in CSMSs compared with those in
the placebo group to calculate the number of patients required.19 For the
FIG 3. A, Line plot of mean scores of the main end point after 1 year of immunotherapy. Low dose,
0.25 mg/mL Alt a 1; high dose, 0.46 mg/mL Alt a 1; and placebo, treatment without Alt a 1. B, t Test comparing
the 3 groups after the first year of treatment. S & M, Symptom and medication score.
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t test to evaluate differences between the active groups and the placebo group.
The paired t test was used to make within-group comparisons throughout the
trial. In the safety section the prevalence of AEs was tested by using a
contingency table and a 2-tailed x2 test. The CI was 95% for all tests.
Data management and graphical representations were made by using the
GraphPad Prism statistical package (version 7.02 for Windows; GraphPad
Software, La Jolla, Calif).RESULTS
Of the 111 patients (ITT population), 17 did not complete the
first year of treatment, 13 were lost to follow-up, 1 withdrew
because of an AE, there was 1 protocol violation, the investigator
decided towithdraw 1 patient, and 1met the exclusion criteria. Of
the 94 ITT patients who completed the trial, 30 were not included
for analysis of the main end point, 29 because they did not have a
CSMS or because it was incomplete or illegible. One protocol
violation was also recorded. For this reason, it was not possible to
analyze the main end point in the ITT population. Therefore the
main end point was evaluated in the per-protocol (PP) population
of 64 patients (37 male) distributed as follows: placebo group,
15 patients; low-dose group, 20 patients; and high-dose group,
29 patients (Fig 2).
Baseline values for the main end point were similar in all
groups (Fig 3, A), and then a trend toward reduction in CSMS in
the high-dose group compared with the other 2 groups was
observed (see Fig E1 in this article’s Online Repository at
www.jacionline.org). At 12 months, the CSMSs in the
high-dose group, in which patients had received a cumulative
dose of Alt a 1 of 4.99 mg, was significantly lower than those in
the placebo group (P5 .046; Fig 3, B). No significant differences
were found between the low-dose and placebo groups after 1 year
of treatment. The low-dose group showed a 26% improvement
over placebo at 12 months, with a cumulative dose of Alt a 1 of
2.70 mg compared with the high-dose group, which showed a
63% improvement over placebo. Between-group analysis
(low dose vs high dose) showed a reduction in the high-dose group
of 50% at the end of both the first and second years, with a
cumulative dose of 9.43 mg of Alt a 1 with respect to the
low-dose group; the P value was .14 and .27 for the first and
second years, respectively. In the placebo/high-dose group, which
received high-dose treatment during the second year, the CSMS
was reduced by 42% compared with the first year.
The ITTwas included in the analysis of secondary end points.
Wheal areas (n 5 111) and serum samples (n 5 110) wereanalyzed. Cutaneous skin prick test responses to Alt a 1
(10 mg/mL) and A alternata (2 HEPD) during the trial
showed a significant reduction in wheal area with respect to
placebo in both cases (P < .05, Fig 4). The same analysis was
performed in the 64 patients who fulfilled the main end
point, and the same significant between-group comparisons
were found (see Fig E2 in this article’s Online Repository at
www.jacionline.org).
In the low-dose and high-dose groups, the wheal area was
reduced by 49% and 56% with the A alternata extract,
respectively, and by 55% and 63% with the Alt a 1 skin prick
test compared with placebo at 12 months. At 24 months of
immunotherapy, an additional reduction of 22% in the wheal
area with the extract of A alternata and 26% with Alt a 1 were
observed in the low-dose group. In the high-dose group the
reduction in wheal area was 14% for A alternata and 29% for
Alt a 1. Between-group analysis (low dose vs high dose) showed
a greater reduction in the high-dose group of 13% and 18% in the
first year with skin prick tests to A alternata and Alt a 1,
respectively, and 5% and 21%, respectively, in the second year.
In some patients from both groups, there was a reduction in wheal
area of less than 9 mm2, which is not considered a positive wheal
response.20 In the low-dose group 30% of A alternata and 33% of
Alt a 1 skin prick tests resulted in a wheal area of less than 9 mm2
at 24 months. In active group 2 the results were 33% for
A alternata and 47% for Alt a 1.
Levels of specific IgE to Alt a 1 increased at 3 months of
immunotherapy in the 2 active groups compared with the placebo
group (P < .05). The greatest reduction was 29% at 24 months
with respect to baseline for the high-dose group (P 5 .0018;
Fig 5, A). Specific IgG4 levels to Alt a 1 increased continuously
in the 2 active groups, whereas levels in the placebo group
remained unchanged from baseline to 12 months (Fig 5, B).
The design of the clinical trial included blind opening of the
placebo group at 12 months and assignment of patients to the
high-dose group during the second year. Fig 6 shows this group
behaved analogously to the high-dose group during the first
year of treatment, with a significant increase in IgE levels during
the first 3 months and a subsequent reduction together with a
significant increase in IgG4 levels as soon as high-dose treatment
began. Skin prick test responses showed a reduction of almost
50% for both A alternata and Alt a 1, resulting in negative skin
test results in 38% of patients.
The IgG4/IgE (in micrograms per liter) ratio increased as doses
were administered in the active groups as a consequence of the
FIG 4. Mean wheal areas of skin prick tests with A alternata (A) and Alt a 1 (B) by group after 1 and 2 years of
immunotherapy. *P < .05 compared with baseline. n, Number of patients analyzed at each visit.
FIG 5. Specific IgE and IgG4 Alt a 1 levels during immunotherapy for the 3 treatment groups. A, Specific IgE
Alt a 1 level (means). B, Specific IgG4 Alt a 1 level (means). *P < .05.
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the placebo group no increase was observed during the first year,
but after the second year, when the high-dose concentration was
administered, the ratio increased 19-fold with respect to the value
of the placebo group at 12 months. The increase in the IgG4/IgE
ratio after 12months of treatment compared with baselinewas 13-
fold for the low-dose group and 28-fold for the high-dose group.
At 24months, the increasewas 24-fold for the low-dose group and
50-fold for the high-dose group (Table I).
Throughout the trial, 1168 AEs were reported, including 5
serious AEs, with no between-group differences. All serious AEs
were considered unrelated to study medication; consequently, no
serious ADRs occurred. Of these AEs, 240 (20.5%) were
considered related to the study medication, and 13 (5.4%) were
reported as local immediate reactions, 172 (71.7%) as local late
reactions, 38 (15.8%) as grade 1 systemic reactions, and 17
(7.1%) as grade 2 systemic reactions. One hundred eighty-one
ADRs were reported during the first year, and 59 were reported
during the second year. Overall, there were no significant
between-group differences in the incidence of ADRs per 100
injection visits compared with the placebo group (Table II) for
each type of reaction; a significant decrease in the incidence
was observed during the second year, especially in the
placebo/high-dose group, in which the proportion was reduced
by more than 7 points in the second year. No serious ADRswere reported throughout the study, and no systemic ADRs
more severe than WAO grade 2 were reported.18DISCUSSION
There are few studies of fungal immunotherapy with
A alternata21-25 and only 1 with the major allergen Alt a 1 purified
in its natural form.13 Alt a 1 is an allergen that is exclusive to the
Fungi kingdom and has a prevalence of greater than 90% in
patients sensitized to A alternata and species of other genera of
the order Pleosporales.12 Its use in immunotherapy provides
a response to the heterogeneity of allergen extracts of
A alternata26-28 common to this source of sensitization.2,29
The results of our study show that allergen immunotherapy
with Alt a 1 is associated with a significant improvement in
CSMSs. The low- and high-dose groups both showed a reduction
in CSMSs15,30,31 at 12 months of treatment of 26% and 63%,
respectively, compared with the placebo group, and this reduction
was statistically significant in the group treated with the high
dose. This suggests benefits for the patient because there are
clinical improvements after a single year of treatment. The
most effective dose of Alt a 1 is 0.37 mg. For pharmaceutical
development reasons, the highest dose tested was 0.37 mg of
Alt a 1, which was almost twice the previously tested dose
(0.2 mg).
FIG 6. A and B, Specific IgE (Fig 6, A) and IgG4 (Fig 6, B) Alt a 1 levels during immunotherapy for the
placebo/high-dose group. C and D, Mean wheal areas of skin prick tests with A alternata (Fig 6, C) and
Alt a 1 (Fig 6, D). *P < .05.
TABLE I. IgG4/IgE ratios in micrograms per liter and increases at 12 and 24 months
Group Baseline 12 mo Increase at 12 mo 24 mo Increase at 24 mo
Placebo 1.673 1.743 No increase NA NA
Low dose 1.888 24.887 13-fold 46.224 24-fold
High dose 1.349 37.614 28-fold 67.337 50-fold
Placebo–high dose NA NA NA 32.853 19-fold
NA, Not applicable.
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serrated profile that is attributable to the number of patients per
group and the presence of spores in the environment. However,
in the study of CSMS trends (see Fig E1), it can be clearly seen
how, from the start, there is a tendency in the high-dose group
toward a decrease in score and therefore an improvement in
CSMS.
In addition, wheal areas of skin prick test responses with
A alternata and Alt a 1 were significantly reduced in the 2 active
groups at 12 months: 47% of patients in the high-dose group and
33% in the low-dose group had awheal area of less than 9mm2 on
skin prick tests with Alt a 1.
Serologic studies showed the classic increase in specific IgE
levels at the beginning of immunotherapy and a subsequent
reduction of 29% at 24 months in the high-dose group. The
increase in the IgG4 response, which was associated with a
nonpathogenic32 and protective33 role induced by immuno-
therapy,34,35 was evident in the low- and high-dose groups from
the third month of immunotherapy onward, with significant
differences in both groups compared with placebo at 3 and
12 months. At 12 and 24 months, IgG4 levels were greater in
the high-dose group than in the low-dose group. This suggests
that the increase in IgG4 levels is, at least in part, dependent on
the dose of allergen administered and is consistent with the
importance of the route of exposure in the response.36 The
significance of the behavior of immunoglobulins as biomarkersin hypersensitivity, as advocated by the European Academy of
Allergy and Clinical Immunology Position Paper,37 was shown
by the Alt a 1–specific IgG4/IgE (in micrograms per liter) ratio,
which showed 13- and 28-fold increases in the low-dose and
high-dose groups, respectively, at 12 months and 24- and
50-fold increases at 24 months.
No between-group differences were found in the ratio of
patient-reportedADRs per 100 injectionvisits at 12months. After
inclusion of the placebo group in the high-dose group, no
between-group differences were found in the ratio of
patient-reported AEs and ADRs per 100 injection visits at
24 months. This suggests that the safety profile of the 2 active
groups was similar to that of the placebo group. Despite the study
not being able to identify ADR reporting differences, these were
reported by 55% of patients, showing a predominantly lower
prevalence than published results.18 As expected for
immunotherapy treatment, ADRs were more frequently reported
by immunotherapy group patients. However, 77% were local
delayed ADRs, for which prevalence and incidence per injection
visit were significantly lower and showed no between-group
differences in the second year.
Each reported symptom was coded according to the MedDRA
dictionary, each event reported (other than those which were
unrelated) was considered an ADR, and nonspecific systemic
ADRs, probably not IgE mediated and without clinical relevance
(24% of reported ADRs), were included in the analysis in line
TABLE II. Ratio of ADRs per 100 injection visits according to group and year of treatment
Type of ADR
Year 1 Year 2
Placebo (n 5 29) Active 1 (n 5 37) Active 2 (n 5 45) Placebo–active 2 (n 5 22) Active 1 (n 5 32) Active 2 (n 5 40)
Local immediate 0.3 0.4 0.5 0.0 0.3 1.3
Local delayed 8.7 7.8 9.3 2.1 3.2 3.5
Total local 9.0 8.2 9.8 2.1 3.5 4.8
Grade 1 0.5 2.7 1.5 0.6 2.1 0.2
Grade 2 0.5 0.5 0.9 0.0 1.3 0.2
Total 10.0 11.4 12.2 2.7 6.9 5.2
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ADRs more severe than WAO grade 2 were reported throughout
the study.
This is the first clinical trial that has shown the efficacy and
safety of allergen immunotherapy with a single protein, Alt a 1.
The demonstration of its efficacy is based on the results obtained
for the main end point, according to the application guideline,15 is
based on the patient’s CSMSs in 2 one-year treatment periods.
There are several problems with this measuring tool, such as its
subjectivity because it consists of self-assessment by the patient.
However, we have seen that for the high dose, it was sensitive
enough to demonstrate a significant clinical improvement.
Although in the low-dose group the improvement was not
statistically significant, contradicting the surrogate efficacy
results studied as secondary end points, such as reduction in
skin test results and immunoglobulin levels, which showed an
improvement.
Another of the factors that could explain this loss of sensitivity
is the exclusion of patients associated with noncompliance with
the case report form (CRF). As many as 29 patients from the 3
treatment groups had to be excluded from the analysis of the main
end point as a consequence of losing or failing to complete the
CRF or providing an illegible CRF. This meant that analysis of the
main end point had to be performed on the PP rather than ITT
population, as recommended for this type of trial. However, in our
opinion this does not invalidate the results obtained because the
randomization effect has not been violated or biased in the PP
population because the original proportion of patients per group
has been maintained, the percentage of patients excluded from
each of the groups for the PP population was similar (between
27.5% and 32%), and this patient exclusion was not related to a
differential intervention in the groups.
Another of the limitations of this study is the number of patients
available for the efficacy analysis. However, this number is in line
with previous studies with fungi, allowing us to make conclusion
on the efficacy and safety of immunotherapy with fungi.
The final composition of the groups, the number of patients in
the high-dose was almost double that of the placebo group and
27% more patients in the low-dose group than in the placebo
group. However, this does not affect the results because designs in
which the active groups contain twice the numbers of the placebo
group are valid.
In summary, our results show the efficacy and safety of
subcutaneous immunotherapy with Alt a 1, the major allergen
of A alternata, at a greater dose than usual in patients with allergic
rhinitis. There was a clear association between the increased dose
of Alt a 1 and greater clinical improvement, as shown by the
CSMS and a reduction in IgE levels together with an increase
in IgG4 levels. The reduction in skin test reactivity was similarin both active groups. In addition, there was an association
between clinical improvements in patients treated with the high
dose of Alt a 1 and 2 biomarkers, skin tests against extracts of
A alternata and Alt a 1, with a percentage of negative wheals of
nearly 50% and an increase in the IgG4/IgE ratio of up to 50-fold.
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Clinical implications: Treatment of hypersensitivity with a
single protein demonstrates efficacy and safety. There was
improvement of 63% in CSMSs in a single year of treatment.
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FIG E1. Trends obtained bymeans of linear regression of CSMSs of each of
the groups during the first year of the trial. Low dose, 0.25 mg/mL Alt a 1;
high dose, 0.46 mg/mL Alt a 1; and placebo, treatment without Alt a 1.
S & M, Symptom and medication score.
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FIG E2. Mean wheal areas of skin prick tests with A alternata (A) and Alt a 1 (B) by group after 1 and 2 years
of immunotherapy in the PP population. *P < .05 compared with baseline. n, Number of patients analyzed at
each visit.
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TABLE E1. Administration schedule and cumulative doses of Alt a 1 per group
Low-dose group High-dose group Placebo group





























































Cumulative dose, first year 2.70 4.99 0
Monthly 12 3 0.8 0.2 0.37 0.37
Cumulative dose, second year 5.10 9.43 9.43*
*Includes induction phase and maintenance doses in the same regimen as the high-dose group during the first year of treatment.
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